We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+6.55%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$467M
AUM Growth
-$27.9M
Cap. Flow
-$12.7M
Cap. Flow %
-2.72%
Top 10 Hldgs %
72.26%
Holding
31
New
2
Increased
2
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$21.5M
2
ZGNX
Zogenix, Inc.
ZGNX
+$4.03M
3
SLNO
Soleno Therapeutics
SLNO
+$2.1M
4
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$49.7K

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$29.5M
2
AIMT
Aimmune Therapeutics
AIMT
+$4.3M
3
SBBP
Strongbridge Biopharma plc.
SBBP
+$3.19M
4
RVNC
Revance Therapeutics, Inc.
RVNC
+$2.13M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$957K

Sector Composition

Rank Sector Weight
1 Healthcare 91.64%
2 Materials 2.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$70.8M 15.16%
1,766,832
– –
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$53.3M 11.42%
1,976,818
– –
ACRS icon
3
Aclaris Therapeutics
ACRS
$744M
$40.6M 8.7%
1,647,214
-1,211,355
-42% -$29.5M
APLS
4
DELISTED
Apellis Pharmaceuticals
APLS
$31.6M 6.78%
+1,457,834
New +$21.5M
CDXS icon
5
Codexis
CDXS
$136M
$25.5M 5.46%
3,054,825
– –
EIGR
6
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$25M 5.35%
59,709
+139
+0.2% +$49.7K
NBRV
7
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$24.4M 5.22%
16,297
– –
AIMT
8
DELISTED
Aimmune Therapeutics
AIMT
$24.3M 5.21%
643,626
-133,187
-17% -$4.3M
KALA icon
9
KALA BIO
KALA
$12.3M
$21.4M 4.59%
464
– –
AAAP
10
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$20.3M 4.36%
249,241
– –
SBBP
11
DELISTED
Strongbridge Biopharma plc.
SBBP
$17.8M 3.81%
2,452,397
-510,248
-17% -$3.19M
VRNA
12
DELISTED
Verona Pharma
VRNA
$17.7M 3.8%
1,492,951
– –
KDMN
13
DELISTED
Kadmon Holdings, Inc.
KDMN
$12.1M 2.58%
3,333,333
– –
RNAC icon
14
Cartesian Therapeutics
RNAC
$225M
$11M 2.35%
37,306
– –
AMRS
15
DELISTED
Amyris Inc.
AMRS
$10.6M 2.27%
2,826,711
– –
SRRA
16
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$9.1M 1.95%
60,957
– –
SLNO
17
DELISTED
Soleno Therapeutics
SLNO
$7.26M 1.56%
268,902
+72,965
+37% +$2.1M
ZLAB icon
18
Zai Lab
ZLAB
$2.1B
$6.74M 1.44%
317,567
-7,433
-2% -$198K
AUPH icon
19
Aurinia Pharmaceuticals
AUPH
$1.92B
$5.5M 1.18%
1,213,290
– –
RGNX icon
20
Regenxbio
RGNX
$615M
$5.47M 1.17%
164,403
– –
FOMX
21
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$5.14M 1.1%
855,000
– –
ZGNX
22
DELISTED
Zogenix, Inc.
ZGNX
$4.21M 0.9%
+105,000
New +$4.03M
AGRX
23
DELISTED
Agile Therapeutics
AGRX
$4.07M 0.87%
757
– –
KALV
24
DELISTED
KalVista Pharmaceuticals
KALV
$2.93M 0.63%
300,325
– –
TRVN
25
DELISTED
Trevena, Inc.
TRVN
$2.77M 0.59%
2,765
– –
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q4 2017 Portfolio in Review

As of Q4 2017, Vivo Capital held 31 positions worth $467M, down 5.6% from $495M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Vivo Capital's Q4 2017 filing shows 2 new, 2 increased, 6 reduced and 1 closed positions. Its largest new stake was Apellis Pharmaceuticals: 1,457,834 shares worth $31.6M. The largest sale was Aclaris Therapeutics, an estimated $29.5M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier, followed by Materials.

  • Vivo Capital's largest Q4 2017 buy was Apellis Pharmaceuticals: 1,457,834 shares worth $31.6M.
  • Vivo Capital added most to Soleno Therapeutics in Q4 2017, an estimated $2.1M increase.
  • Vivo Capital's biggest Q4 2017 reduction was Aclaris Therapeutics, cutting an estimated $29.5M.
  • Vivo Capital fully exited Revance Therapeutics, Inc. in Q4 2017, selling an estimated $2.13M.
  • Vivo Capital's ten largest holdings make up 72% of its $467M portfolio in Q4 2017.
  • Vivo Capital opened 2 new positions and closed 1 in Q4 2017.
  • Vivo Capital's portfolio value fell 5.6% quarter-over-quarter to $467M.

Based on Vivo Capital's 13F filing for Q4 2017, filed 9 Feb 2018.